Skip to main content
Log in

Therapy-free interval has prognostic value in patients with recurrent cervical cancer treated with chemotherapy following definitive concurrent chemoradiotherapy: methodological issues

  • Correspondence
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kozaki M, Sakuma S, Kudaka W, Kinjyo Y, Taira Y, Arakaki Y, Shimoji Y, Nakasone T, Nakamoto T, Wakayama A, Ooyama T (2017) Therapy-free interval has prognostic value in patients with recurrent cervical cancer treated with chemotherapy following definitive concurrent chemoradiotherapy. Arch Gynecol Obstet 296(5):997–1003

    Article  PubMed  Google Scholar 

  2. Kleinbaum DG, Klein M (2010) Survival analysis. Springer, New York

    Google Scholar 

  3. Hosmer DW Jr, Lemeshow S, Sturdivant RX (2013) Applied logistic regression. Wiley, New York

    Book  Google Scholar 

  4. Steyerberg EW (2008) Clinical prediction models: a practical approach to development, validation, and updating. Springer Science & Business Media, New York

    Google Scholar 

Download references

Funding

There is no funding for this article.

Author information

Authors and Affiliations

Authors

Contributions

Conception of study design: AAA and SS. Drafting manuscript: AAA and SS. Critically revised manuscript: AAA and SS. All authors approved the final version for submission.

Corresponding author

Correspondence to Saeid Safiri.

Ethics declarations

Conflict of interest

We have no conflict of interest as to this article.

Ethical approval

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ashrafi-Asgarabad, A., Safiri, S. Therapy-free interval has prognostic value in patients with recurrent cervical cancer treated with chemotherapy following definitive concurrent chemoradiotherapy: methodological issues. Arch Gynecol Obstet 297, 805–806 (2018). https://doi.org/10.1007/s00404-017-4629-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-017-4629-9

Navigation